Novartis expands molecular glue program as Medicare drug spending surges and biotech firms report new data and funding
Novartis announced it is deepening its investment in molecular glue technology, a platform that aims to target previously undruggable proteins. The move signals the company’s confidence in the approach as it seeks new therapeutic opportunities.
Medicare’s prescription drug spending is climbing faster than expected, driven largely by increased use of GLP‑1 medicines and the ongoing effects of recent changes to the Part D benefit design.
In related biotech news, Enliven reported encouraging early‑stage results for its leukemia candidate, while SonoThera secured $125 million to advance an ultrasound‑based method for delivering gene therapies.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Novartis doubles down on molecular glue strategy”
read at STAT ↗
comments(0)
5-min edit window · permanent after that